Katholisches Krankenhaus Hagen St Josefs Hospital
- Address
- Dreieckstr.17, 58097 Hagen, Germany
Katholisches Krankenhaus Hagen St Josefs Hospital - Hematologic Oncology Research
Katholisches Krankenhaus Hagen St Josefs Hospital is actively engaged in advanced clinical research focused on hematologic malignancies, with particular expertise in the treatment of chronic lymphocytic leukemia. The center participates in cutting-edge international multicenter trials investigating novel therapeutic approaches for patients with blood cancers.
- High-risk chronic lymphocytic leukemia (CLL) treatment strategies
- Triple combination targeted therapy regimens including BTK inhibitors and BCL-2 inhibitors
- Risk-stratified treatment approaches for patients with poor prognostic markers
The hospital's research program emphasizes precision medicine approaches for patients with complex karyotypes, TP53 mutations, 17p deletions, and unmutated IGHV status. Through participation in phase 3 randomized trials, the center contributes to the development of optimized therapeutic combinations involving acalabrutinib, obinutuzumab, and venetoclax, aiming to improve progression-free survival outcomes for previously untreated high-risk CLL patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Katholisches Krankenhaus Hagen St Josefs Hospital
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An open-label Phase II/III randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 | BioNTech SE | Phase IV | Recruiting | Mar 2021 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 3 | Unknown | 2018-10-18 | 2026-07-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.